pharmaceutical investing Zynerba Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights
pharmaceutical investing Zynerba Pharmaceuticals Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic Encephalopathies
Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake